Pacira Pharma Cash Flow - Quarterly (NASDAQ:PCRX)

Add to My Stocks
$52 $0.65 (1.27%) PCRX stock closing price Sep 20, 2018 (Closing)

The cash flow statement is one of the reports a publicly traded company like Pacira Pharma needs to disclose. This statement shows details about the cash generated and spent during a particular quarter, while the other two statements give details about Pacira Pharma profits and Pacira Pharma debt. This statement can tell if a company is running out of money while still being profitable and is useful in Pacira Pharma stock analysis. Pacira Pharma had a negative net income cash flow of $-8.12M till this quarter of 2018 Q2. This report is very useful in measuring the short term viability of a company. Pacira Pharma had an inflow of $11.02M from operating activities, $2.44M inflow due to financing activities, and $49.28M inflow due to investing activities till 2018 Q2.

View and download details of Pacira Pharma cash flows for latest & last 40 quarters
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Net Income Cash Flow
-8.12M-10.68M-42.61M-47.2M-39.6M-19.86M-37.94M-33.97M-11.81M-3.85M
Depreciation Depletion Amortization Cash-Flow12.68M6.26M25.5M18.42M11.69M4.68M17.48M13.08M8.66M4.3M
Net Increase (Decrease) in Assets Liabilities-8.98M-6.67M-2.57M-11.06M3.93M22.27M13.48M-8.58M-12.06M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net15.44M8.39M37.46M29.27M20.5M11.25M31.63M23.51M16.15M8.49M
Net Cash from (used by) Operating Activities
11.02M-2.68M17.78M-3.66M-33.45M16.1M4.42M-3.12M
Increase (Decrease) in Prop Plant And Equipment-7.82M-5.18M-19.26M-14.19M-8.77M-3.61M-24.7M-19.82M-15.92M-7.05M
Acquisition Disposition of Subsidiaires-4.72M-2.29M-8.46M-6.21M-4.2M-2.09M-15.85M-13.79M-3.87M-1.9M
Increase (Decrease) in Investments61.81M-2.81M-196.03M-212.05M-192M-138.12M-21.18M-21.22M-21.72M-12.91M
Other Cash Inflow (Outflow) from Investment Activities----------
Net Cash from (used by) Investment Activities
49.28M-10.29M-223.76M-232.46M-204.98M-143.83M-61.75M-54.83M-41.51M-21.87M
Issuance (Purchase) of Equity Shares2.44M-8.64M6.36M3.66M-7.26M6.19M5.42M3.04M
Issuance (Repayment) of Debt Securities--226.8M226.8M226.52M227M----
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities---11.28M-11.28M-11M-11M----
Net Cash from (used by) Financing Activities
2.44M-224.16M221.88M219.19M216.85M7.26M6.19M5.42M3.04M
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
62.75M-12.56M18.18M-9.72M17.87M73.02M-21.04M-32.54M-31.67M-21.95M
Cash & Equivalents at Beginning of Year54.13M35.94M56.98M37.52M12.51M10.12M46.16M26.13M7.07M12.38M
Cash & Equivalents at Year End116.87M41.56M54.12M26.21M53.81M108.97M35.94M24.44M25.3M35.02M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The Pacira Pharma stock price history and Pacira Pharma stock comparison chart inevitably reflect its cash flow situation.

  • Net Change in Cash and Cash Equivalents: A positive net change in cash and cash equivalents shows that Pacira Pharma is able to meet its expenditure and grow cash at hand which demonstrates the financial strength of the company's balance sheet. Also see - Pacira Pharma stock price movement.
  • Pacira Pharma increased its cash from operating activities to $11.02M till 2018 Q2. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Growth companies, typically most tech companies; spend heavily on investing activities and this figure stood at $49.28M for PCRX stock. Sometimes a company might have a negative overall cash flow which may not be really bad if it is due to investment expenses. Hence it is important to check the cash flow from investment activities.
  • Cash flow from financing activities shows the flow of cash between Pacira Pharma and its owners and creditors and was $2.44M till 2018 Q2. Financing activities allow a company to raise capital, and repay bondholders.

Key Financial Ratios For Pacira Pharma Cash Flow

FCF margin
0.13

Quarterly Cash Flow Statements For Pacira Pharmaceuticals Inc Peers

AcelRx Pharma cash flow, Cara Therapeutics cash flow, Durect cash flow, Spectrum Pharma cash flow